News | May 15, 2024
IOL Chemicals and Pharmaceuticals posts Q4 FY24 consolidated PAT at Rs. 27.62 Cr
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Signs MoU with the Govt. of Gujarat at Vibrant Gujarat Summit
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
Subscribe To Our Newsletter & Stay Updated
